Sunday - November 15, 2026
Phase III ELSPIRE Trial Results Published in HEPATOLOGY Demonstrates Elafibranor Achieves ALP Normalization in More Than 85% of Patients with Primary Biliary Cholangitis
November 05, 2026
ALEXANDRIA, Virginia, Nov. 5 [Category: Medical] -- The American Association for the Study of Liver Diseases posted the following news:

* * *

Phase III ELSPIRE Trial Results Published in HEPATOLOGY Demonstrates Elafibranor Achieves ALP Normalization in More Than 85% of Patients with Primary Biliary Cholangitis

*

Elafibranor significantly improved key markers of disease activity compared with placebo, supporting ALP normalization as an achievabl . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products